Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study

Detalhes bibliográficos
Autor(a) principal: Braga, Eduardo Lorens
Data de Publicação: 2006
Outros Autores: Lyra, André Castro, Nascimento, Lourianne, Martins Netto, Eduardo, Kalabrik, Luciano, Lyra, Luiz Guilherme Costa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://www.repositorio.ufba.br/ri/handle/ri/5987
Resumo: p.275-279
id UFBA-2_1442cdb9dc4e0e7d1fd1b6637c894fbf
oai_identifier_str oai:repositorio.ufba.br:ri/5987
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Braga, Eduardo LorensLyra, André CastroNascimento, LourianneMartins Netto, EduardoKalabrik, LucianoLyra, Luiz Guilherme CostaBraga, Eduardo LorensLyra, André CastroNascimento, LourianneMartins Netto, EduardoKalabrik, LucianoLyra, Luiz Guilherme Costa2012-05-30T13:18:37Z2012-05-30T13:18:37Z2006-100004-2803http://www.repositorio.ufba.br/ri/handle/ri/5987v. 43, n.4p.275-279Background - Studies on hepatitis C virus kinetics showed that serum levels of interferon fall 48 h after drug administration, when viral load is increasing again. Previously to the availability of pegylated interferon, daily induction therapy with standard interferon was under evaluation. Aims - To evaluate the safety and effi cacy of interferon alpha daily induction regimen in combination with ribavirin. Patients and methods - A randomized trial including 93 patients with chronic hepatitis C was carried out. On satisfying all eligibility criteria, patients were randomly allocated to two different treatment groups: 44 individuals in treatment arm A: IFN 3 MU thrice weekly + ribavirin 1.0-1.2 g daily for 48 weeks (IFN TIW) and 49 individuals in treatment arm B: IFN 3 MU daily + ribavirin 1.0-1.2 g daily for 12 weeks followed by IFN 3 MU thrice weekly + ribavirin 1.0-1.2 g daily, until completion of 48 weeks of therapy (IFN QD). HCV genotyping was obtained in 85 subjects. A negative HCV-RNA 6 months after cessation of therapy was considered a sustained virological response. Results - Eighty three patients completed treatment, fi ve dropped out (one from IFN TIW and four from IFN QD) and in fi ve patients therapy was discontinued due to medical request (two from IFN TIW and three from IFN QD). There was no statistically signifi cant difference between groups with respect to therapy interruption. The frequency of cirrhosis was 29%, similar in both groups. In the “intention to treat” analysis the overall sustained virological response was 39.8%. There was no signifi cant difference in sustained virological response rate between both treatment strategies (36.4% IFN TIW vs 42.9% IFN QD). In the 83 patients who fi nished the trial, sustained virological response was 44.6%. Among subjects with HCV genotype-1, the sustained virological response was 42% (40.9% IFN TIW vs 42.9% IFN QD) and among patients with HCV genotype 2 or 3, the sustained virological response was 55.6% (50% IFN TIW vs 63.6% IFN QD). Conclusions – Combination therapy had an overall sustained virological response rate of 39.8% (“intention to treat analysis”). There was no difference with respect to sustained virological response rates between patients who used daily induction schedule compared to standard regimen. Adverse events, even more frequent in the daily induction group, did not interfere with the treatment strategies.Submitted by Texeira Ana (atanateixeira@gmail.com) on 2012-05-30T13:18:37Z No. of bitstreams: 1 Braga, Eduardo Lorens.pdf: 74960 bytes, checksum: 9e4308775a7d93d9addab5d7cd926797 (MD5)Made available in DSpace on 2012-05-30T13:18:37Z (GMT). No. of bitstreams: 1 Braga, Eduardo Lorens.pdf: 74960 bytes, checksum: 9e4308775a7d93d9addab5d7cd926797 (MD5) Previous issue date: 2006-10São PauloEBEPEGEhttp://dx.doi.org/10.1590/S0004-28032006000400006reponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBAHepatitis CInterferon alfa 2-aInterferon alfa-2bRibavirinDaily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized studyArq. Gastroenterolinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleenginfo:eu-repo/semantics/openAccessORIGINALBraga, Eduardo Lorens.pdfBraga, Eduardo Lorens.pdfapplication/pdf74960https://repositorio.ufba.br/bitstream/ri/5987/1/Braga%2c%20Eduardo%20Lorens.pdf9e4308775a7d93d9addab5d7cd926797MD51LICENSElicense.txtlicense.txttext/plain1762https://repositorio.ufba.br/bitstream/ri/5987/2/license.txt1b89a9a0548218172d7c829f87a0eab9MD52TEXTBraga, Eduardo Lorens.pdf.txtBraga, Eduardo Lorens.pdf.txtExtracted texttext/plain26713https://repositorio.ufba.br/bitstream/ri/5987/3/Braga%2c%20Eduardo%20Lorens.pdf.txt900f93264395d6f81fc3fbd58395a045MD53ri/59872022-08-08 13:17:39.443oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-08-08T16:17:39Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study
dc.title.alternative.pt_BR.fl_str_mv Arq. Gastroenterol
title Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study
spellingShingle Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study
Braga, Eduardo Lorens
Hepatitis C
Interferon alfa 2-a
Interferon alfa-2b
Ribavirin
title_short Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study
title_full Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study
title_fullStr Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study
title_full_unstemmed Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study
title_sort Daily interferon induction regimen using different manufactured interferons (alpha-2a or alpha-2b) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study
author Braga, Eduardo Lorens
author_facet Braga, Eduardo Lorens
Lyra, André Castro
Nascimento, Lourianne
Martins Netto, Eduardo
Kalabrik, Luciano
Lyra, Luiz Guilherme Costa
author_role author
author2 Lyra, André Castro
Nascimento, Lourianne
Martins Netto, Eduardo
Kalabrik, Luciano
Lyra, Luiz Guilherme Costa
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Braga, Eduardo Lorens
Lyra, André Castro
Nascimento, Lourianne
Martins Netto, Eduardo
Kalabrik, Luciano
Lyra, Luiz Guilherme Costa
Braga, Eduardo Lorens
Lyra, André Castro
Nascimento, Lourianne
Martins Netto, Eduardo
Kalabrik, Luciano
Lyra, Luiz Guilherme Costa
dc.subject.por.fl_str_mv Hepatitis C
Interferon alfa 2-a
Interferon alfa-2b
Ribavirin
topic Hepatitis C
Interferon alfa 2-a
Interferon alfa-2b
Ribavirin
description p.275-279
publishDate 2006
dc.date.issued.fl_str_mv 2006-10
dc.date.accessioned.fl_str_mv 2012-05-30T13:18:37Z
dc.date.available.fl_str_mv 2012-05-30T13:18:37Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.repositorio.ufba.br/ri/handle/ri/5987
dc.identifier.issn.none.fl_str_mv 0004-2803
dc.identifier.number.pt_BR.fl_str_mv v. 43, n.4
identifier_str_mv 0004-2803
v. 43, n.4
url http://www.repositorio.ufba.br/ri/handle/ri/5987
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv EBEPEGE
publisher.none.fl_str_mv EBEPEGE
dc.source.pt_BR.fl_str_mv http://dx.doi.org/10.1590/S0004-28032006000400006
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/5987/1/Braga%2c%20Eduardo%20Lorens.pdf
https://repositorio.ufba.br/bitstream/ri/5987/2/license.txt
https://repositorio.ufba.br/bitstream/ri/5987/3/Braga%2c%20Eduardo%20Lorens.pdf.txt
bitstream.checksum.fl_str_mv 9e4308775a7d93d9addab5d7cd926797
1b89a9a0548218172d7c829f87a0eab9
900f93264395d6f81fc3fbd58395a045
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1808459399568556032

Registros relacionados